The largest database of trusted experimental protocols

U 0126

U 0126 is a selective inhibitor of the mitogen-activated protein kinase (MAPK) kinase enzymes MEK1 and MEK2, which are essential components of the MAPK/ERK signaling pathway.
This pathway regulates cell growth, differentiation, and survival in response to extracellular signals.
U 0126 blocks the activation of ERK1 and ERK2, the downstream effectors of MEK1/2, thereby inhibiting MAPK/ERK signaling.
It has been widely used as a tool compound to investigate the role of this signaling cascade in various cellular processes and disease models.
Researchers can utilize the PubCompare.ai platform to discover optimized protocols for the use of U 0126 and acheive better, more reproducible results in their studies.

Most cited protocols related to «U 0126»

Epidermal keratinocytes were isolated from human foreskin as previously described (Halbert et al., 1992 (link)). The cells were propagated in medium 154 supplemented with human keratinocyte growth supplement, 1,000× gentamycin/amphotericin B solution (Invitrogen), and 0.07 or 0.2 mM CaCl2.
Keratinocytes were transduced with retroviral supernatants produced from Phoenix cells (provided by G. Nolan, Stanford University, Stanford, CA) as previously described (Getsios et al., 2004 (link)). For differentiation of submerged cultures, cells were grown to confluence and switched to E-medium containing 1.8 mM Ca2+ for 1–6 d (Meyers and Laimins, 1994 (link)). For raft cultures, transduced cells were expanded and grown at an air–medium interface according to published protocols (Meyers and Laimins, 1994 (link)). Organotypic cultures were grown for 3–10 d, at which time they were lysed for RNA/protein analysis, embedded in optimal cutting temperature compound for frozen sections, fixed in 10% neutral-buffered formalin, and embedded in paraffin for histology or fixed in 2% paraformaldehyde/2% glutaraldehyde in cacodylate buffer for EM analysis. For some experiments, cultures were treated with 2–5 µg/ml ETA, DMSO (Thermo Fisher Scientific), 10 µM PKI166 (Novartis), 5 µM U0126 (Cell Signaling Technology), or 10 µM SB203580 (EMD).
Publication 2009
Amphotericin Amphotericin B Buffers Cacodylate Cells Dietary Supplements Epidermis Foreskin Formalin Frozen Sections Gentamicin gentamicin B Glutaral Homo sapiens Keratinocyte Microphysiological Systems Paraffin Embedding paraform PKI 166 Proteins Retroviridae SB 203580 Sulfoxide, Dimethyl U 0126

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
1-Phosphatidylinositol 3-Kinase 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide ADAM17 protein, human Amino Acids Epitopes LY 294002 MG 132 N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide Open Reading Frames PD 98059 Phosphotransferases Plasmids sulfosuccinimidyl 6-(biotinamido)hexanoate TGFBR1 protein, human TGFBR2 protein, human Transforming Growth Factor beta U 0126
Cyclodextrin-encapsulated 17β-estradiol (E2; Sigma, St. Louis, MO) at a dose of 0.2 mg/kg was dissolved in physiological saline in a volume of 4 ml/kg, and injected intraperitoneally (i.p.). This dose in mice facilitates object memory consolidation in the task used here (Gresack and Frick, 2004 (link), 2006 (link)). The vehicle, hydroxypropyl-β-cyclodextrin (HBC), was dissolved in an equal volume of saline and contained the same amount of cyclodextrin as E2. The MEK inhibitor SL327 (α-[Amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl) benzeneacetonitrile; Sigma), at a dose of 30 mg/kg, was dissolved in 100% dimethyl sulfoxide (DMSO) and injected i.p. in a volume of 2.0 ml/kg. Vehicle controls received HBC or both HBC and DMSO. For intrahippocampal (IH) infusions, physiological saline or cyclodextrin-encapsulated E2 dissolved in physiological saline (5.0 μg/0.5μl) was infused at 0.5 μl/min for 1 minute.
To demonstrate that E2-induced increases in object recognition were dependent on dorsal hippocampal ERK activation, other mice received IH infusions of vehicle or the MEK inhibitor U0126 (1,4-Diamino-2,3-dicyano-1,4-bis (o-aminophenylmercapto) butadiene; 2.0 μg/μl; Sigma) concurrently with i.p. E2 injection or intracerebroventricular (ICV) infusion of bovine serum albumin-conjugated 17β-estradiol (see below) into the dorsal third ventricle. U0126 was dissolved in 100% DMSO to 4 μg/μl as a stock solution and then serially diluted in physiological saline for infusion of various doses. U0126 or vehicle (50% DMSO) were infused at a rate of 0.50 μl/min and a volume of 0.50 μl/side. Other mice received ICV infusions of vehicle or bovine serum albumin-conjugated 17β-estradiol (β-Estradiol 6-(O-carboxy-methyl)oxime; BSA-E2; Sigma). The covalent conjugation of E2 to the large BSA molecule prevents E2 from passing through the cell membrane and binding to intracellular ERs (Taguchi et al., 2004 (link)). Thus, effects of BSA-E2 should be mediated by membrane-bound ERs. BSA-E2 was dissolved in Tris-HCl to a concentration of 5.0 μM. Either 5.0 μM BSA-E2 or vehicle (Tris-HCl) was infused at a rate of 0.5 μl/min at a volume of 1.0 μl.
To demonstrate that the effects of BSA-E2 on memory and ERK activation were independent of nuclear estrogen receptors, other mice received ICV infusions of BSA-E2 conducted as described above concurrently with IH infusions of the nuclear estrogen receptor antagonist ICI 182,780 ((7a,17b)-7-[9[(4,4,5,5,5pentafluoropentyl) Sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol; 10 μg/μl; Sigma). ICI 182,780 is an antagonist of ERα and ERβ that impairs E2-induced ER dimerization (Weatherman et al., 2002 (link)) and translocation of ERs into the cell nucleus (Dauvois et al., 1993 (link)). If ICI 182,780 does not block the effects of BSA-E2 on memory and ERK activation, then this would indicate that these effects are mediated by membrane-associated estrogen receptors rather than nuclear receptors. Intrahippocampal infusions of ICI 182,780 were conducted at a rate of 0.5 μl/min and a volume of 0.5 μl/side, resulting in a dose of 5.0 μg/side. In other mice, ICI 182,780 was infused intrahippocampally without concurrent ICV infusion as a control due to a report that this compound in female rats can act as an estrogen receptor agonist to enhance place learning when administered in the absence of E2 (Zurkovsky et al., 2006 (link)). To compare effects of ICI 182,780 with those of traditional E2, 0.2 mg/kg E2 was administered i.p. either alone or with ICI 182,780 infused intrahippocampally. The E2 + IH ICI 182,780 group also served as a control for the effectiveness of the ICI compound in blocking the effects of traditional, non-BSA conjugated E2 on object memory consolidation and ERK activation. Vehicle controls for the aforementioned groups received ICV and IH infusions of saline or BSA dissolved in saline.
Finally, to demonstrate that the effects of BSA-E2 on memory and ERK activation involved the dorsal hippocampus, BSA-E2 was infused bilaterally into the dorsal hippocampus of another set of mice. Intrahippocampal infusions were conducted at a rate of 0.5 μl/min and at a volume of 0.5 μl/side, resulting in doses of 5.0 μM/side. As a control, these mice also received ICV infusions of vehicle (BSA dissolved in saline). Additional mice received ICV BSA-E2 + IH vehicle as a control to replicate the effects of ICV BSA-E2 observed above. As an additional method of demonstrating hippocampal involvement in the BSA-E2 effect, other mice received ICV infusions of BSA-E2 conducted as described above concurrently with IH infusions of the GABAA receptor agonist muscimol (3-Hydroxy-5-aminomethyl-isoxazole; 0.50 μg/μl dissolved in saline; Sigma). Muscimol temporarily inactivates a brain region of interest by increasing GABAergic inhibition without permanently damaging the tissue (Martin, 1991 (link)). Therefore, if muscimol interferes with the beneficial effects of ICV BSA-E2 on memory, then this would suggest critical involvement of the dorsal hippocampus in this effect. Intrahippocampal infusions of muscimol were conducted at the same rate and volume as above. Vehicle controls for all of the aforementioned groups received ICV and IH infusions of saline or BSA dissolved in saline.
Injection cannulae for IH and ICV infusions remained in place for 1 minute after infusion to prevent drug diffusion up the injection track. For behaviorally tested mice, all solutions were administered immediately after the sample phase of object recognition training.
Publication 2008
1,3-butadiene Brain Cannula carbene Cell Nucleus Cyclodextrins Diffusion Dimerization Estradiol estradiol-bovine serum albumin Estrogen Nuclear Receptor estrogen receptor alpha, human Estrogen Receptor Antagonists Females GABA-A Receptor Agonists GPER protein, human Hypromellose ICI 182780 Infusions, Intracerebroventricular Isoxazoles Memory Memory Consolidation Mus Muscimol Oximes Pharmaceutical Preparations physiology Plasma Membrane Protoplasm Psychological Inhibition Rattus Receptors, Nuclear Saline Solution Seahorses Serum Albumin, Bovine Sulfoxide, Dimethyl Tissue, Membrane Tissues Translocation, Chromosomal Tromethamine U 0126 Ventricles, Third
Murine BMDMs were obtained as described17 (link) and maintained in DMEM supplemented with 10% FBS and 10% L929 cell supernatant as conditioned medium providing macrophage colony stimulating factor (M-CSF). Recombinant mouse IFN-γ was from Peprotech and used at 10 ng/ml. Cell culture grade LPS and CHX were purchased from Sigma-Aldrich. Pam3Cys was purchased from EMC Microcollections. LPS was used as 1 ng/ml and Pam3Cys was used at 10 ng/ml unless otherwise noted. A γ-secretase inhibitor GSI-34 was used at 10 µM as previously described46 (link). U0126, SB203580, SP600125, and CGP57380 were from Calbiochem.
Publication 2012
Cell Culture Techniques CGP 57380 Culture Media, Conditioned IFNG protein, mouse L929 Cells Macrophage Colony-Stimulating Factor Mus N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine SB 203580 Secretase SP600125 U 0126

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2018
Animals Brain Calmodulin-Dependent Protein Kinase II chelerythrine Dantrolene Drug Overdose Emetics ERK1-2 Pathway Food GF 109203X GR 73632 inhibitors KN 93 LY 294002 MRS 1845 netupitant Pentobarbital PIK3CG protein, human Shrews Substance P Receptor Tenebrio Triphosphate Receptor, Inositol U 0126 Vomiting YM 58483

Most recents protocols related to «U 0126»

ERK1/2 inhibitor (U0126 solution): U0126 powder was dissolved in dimethyl sulfoxide (DMSO) to 50µM concentration as the storage solution.
STAT3 inhibitor (Stattic solution): Stattic powder was dissolved in DMSO to 20µM concentration as the storage solution.
Full text: Click here
Publication 2023
Mitogen-Activated Protein Kinase 3 Powder STAT3 protein, human stattic Sulfoxide, Dimethyl U 0126
U0126 (MEK1/2 inhibitor) and BAY11-7082 (NF-κB inhibitor) were dissolved in dimethyl sulfoxide (DMSO) (final concentration <1%) as stock solutions. The stock solution was diluted with phosphate-buffered saline (PBS).
All rats were randomly divided into five groups of six rats each; group 1: Sham group, rats were given sham operation and intragastrically administered the same volume of 0.9% NaCl solution, n = 6; group 2: Endo group, rats with autologous uterine tissue transplantation were intragastrically administered the same volume of 0.9% NaCl solution, n = 6; group 3: Endo+DMSO group, EMs rats, which were intraperitoneally injected with vehicle treatment (5% DMSO in 300 μL sterile PBS), n = 6; group 4: Endo+U0126 group, EMs rats, which were intraperitoneally injected with U0126 (20 mg/kg) in vehicle, n = 6; and group 5: Endo+BAY11-7082 group, EMs rats, which were intraperitoneally injected with BAY11-7082 (20 mg/kg) in vehicle, n = 6; all treatments were continued for 4 weeks.
Full text: Click here
Publication 2023
BAY 11-7082 dimethyl phosphate Endometriosis I-kappa B Proteins MAP2K1 protein, human Normal Saline Phosphates Rattus norvegicus Saline Solution Sterility, Reproductive sulfoxide Sulfoxide, Dimethyl Tissues Transplantation, Autologous U 0126 Uterus
The 3-week-old C57BL/6 male mice were randomly divided into 4 groups: control group (n = 22, routine dietary water with intraperitoneal injection of isotonic sodium chloride solution), Cipro group (n = 23, routine dietary water with intraperitoneal injection of ciprofloxacin), BAPN (Aladdin) (1 mg/g/d) group (n = 48, BAPN dissolved in drinking water with intraperitoneal injection of isotonic sodium chloride solution), and BAPN+Cipro group (n = 49, BAPN dissolved in drinking water with intraperitoneal injection of ciprofloxacin). We selected the concentration of ciprofloxacin according to the standard low dose (8.3 mg/kg/d) for the treatment of patients with common indications and converted it to the equivalent dose concentration in mice (40 mg/kg/d, intraperitoneal injection) (48 (link)–50 (link)). In all animal experiments, BAPN diluted in daily drinking water was used for 28 days. Ciprofloxacin or isotonic sodium chloride solution was injected intraperitoneally from weeks 2 to 6. AA/AD was defined as previously described (12 (link)). At the end of the study, the mice were sacrificed, and the aortas were processed for AA/AD evaluation and tissue analysis.
We validated the hypothesis that ciprofloxacin could induce apoptosis through MAPK-dependent activation of Bax/Bcl2 signaling in vivo. Three-week-old C57BL/6 male mice were randomly divided into 3 groups: the BAPN group (n = 35, BAPN dissolved in drinking water with intraperitoneal injection of isotonic sodium chloride solution), BAPN+Cipro group (n = 35, BAPN dissolved in drinking water with intraperitoneal injection of ciprofloxacin), and BAPN+Cipro+MAPK inhibitor group (n = 36, BAPN dissolved in drinking water with intraperitoneal injection of ciprofloxacin and SB203580 [0.5 mg/kg/d] and U0126 [10 mg/kg/d]). In all animal experiments, BAPN was administered for 28 days. Ciprofloxacin or isotonic sodium chloride solution was injected intraperitoneally from weeks 2 to 6, while inhibitors were administered from weeks 1 to 6.
Full text: Click here
Publication 2023
Aminopropionitrile Aorta Apoptosis BCL2 protein, human Cipro Ciprofloxacin Diet inhibitors Injections, Intraperitoneal Males Mice, House Mice, Inbred C57BL Patients Saline Solution SB 203580 Tissues U 0126
The viral titers were determined by TCID50 assay as previously described [29 (link),30 (link)]. Cell lines (Hep-3B, Huh7, and PLC/PRF/5) were infected with viruses at 5 MOI for 0 h, 12 h, 24 h, 36 h, and 48 h. To study how lectins affect viral replication through signaling pathways, some activators or inhibitors (Selleck Chemicals LLC, Houston, TX, USA) were administered, and the drug was used 1 h prior to infection. Agents used in Hep-3B cells were AICAR (400 μmol/L), Sorafenib (3 μmol/L), U0126 (10 μmol/L), SP600125 (5 μmol/L), XMU-MP-1 (2 μmol/L), KY12420 (4.5 μmol/L), Capsaicin (100 μmol/L), and EPI-001 (100 μmol/L). The agents used in Huh7 cells were AICAR (400 μmol/L), Sorafenib (10 μmol/L), U0126 (10 μmol/L), SP600125 (5 μmol/L), XMU-MP-1 (2 μmol/L), KY12420 (4.5 μmol/L), Capsaicin (250 μmol/L), and EPI-001 (100 μmol/L). The agents used in PLC/PRF/5 cell lines were AICAR (400 μmol/L), Sorafenib (10 μmol/L), U0126 (10 μmol/L), SP600125 (5 μmol/L), XMU-MP-1 (2 μmol/L), KY12420 (4.5 μmol/L), Capsaicin (100 μmol/L), and EPI-001 (100 μmol/L).
Full text: Click here
Publication 2023
AICA ribonucleotide Biological Assay Capsaicin Cell Lines Cells EPI 001 Infection inhibitors Lectin Pharmaceutical Preparations Signal Transduction Pathways Sorafenib SP600125 U 0126 Virus Virus Replication XMU-MP-1
After changing the medium to DMEM containing 0.5% FBS and culturing for 24 h, HGFs were treated with Clys (0.1, 1, 2.5, or 5 μM) for 30 min, and total cellular proteins were extracted using lysis buffer (0.5% SDS, 10 mM Tris-HCl pH7.4, and protease inhibitor mix: CompleteTM [Sigma-Aldrich, St. Louis, MO, USA]). Phosphorylation of ERK, JNK, and p-38 was examined using Western blotting. All Western blotting images are representative of three independent experiments. To investigate the potential pathways contributing to Clys-induced inflammation-related molecule production, HGFs were pretreated with U0126 (MEK inhibitor, 10 μM) and SB2013580 (p38 MAPK inhibitor, 10 μM) for 1 h and treated with Clys (5 μM) for 24 h, according to a previous study [39 (link)]. The levels of IL-6 and pro-MMP-1 in the cell culture supernatant were measured using commercially available ELISA kits (R&D Systems).
Full text: Click here
Publication 2023
Buffers Cell Culture Techniques Cells Enzyme-Linked Immunosorbent Assay Inflammation Interstitial Collagenase Mitogen-Activated Protein Kinase p38 Phosphorylation Protease Inhibitors Proteins Tromethamine U 0126

Top products related to «U 0126»

Sourced in United States, Germany, France, China, United Kingdom, Sao Tome and Principe, Macao, Canada, Italy, Japan
U0126 is a selective and potent inhibitor of the mitogen-activated protein kinase (MAPK) kinases, MEK1 and MEK2. It blocks the phosphorylation and activation of the extracellular signal-regulated kinases (ERK1 and ERK2), thereby inhibiting the MAPK/ERK signaling pathway.
Sourced in United States, Germany, United Kingdom, China, France, Japan, Canada
U0126 is a specific inhibitor of the mitogen-activated protein kinase kinase (MEK1 and MEK2). It functions by blocking the activation of MAPK/ERK pathway.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, China, Germany, United Kingdom
U0126 is a specific inhibitor of the mitogen-activated protein kinase kinase (MEK1/2) enzymes. It functions by blocking the activation of extracellular signal-regulated kinases (ERK1/2), which are key components of the MAPK signaling pathway.
Sourced in United States, United Kingdom, France, Germany, China
U0126 is a specific and potent inhibitor of MEK1 and MEK2. It inhibits the activation of ERK1/2 by blocking the dual-specificity kinases MEK1 and MEK2, which are responsible for phosphorylating and activating ERK1/2.
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Macao, Italy, Canada, Switzerland, Japan, France, Israel, Spain, Morocco
LY294002 is a chemical compound that functions as a specific inhibitor of phosphoinositide 3-kinase (PI3K). It is commonly used in laboratory research settings to investigate the role of PI3K signaling pathways.
Sourced in United States, Germany, Macao, United Kingdom, China, Japan, Spain, Switzerland, Canada, Sao Tome and Principe, Sweden, Italy
SB203580 is a lab equipment product manufactured by Merck Group. It is a pyridinyl imidazole compound that functions as a selective inhibitor of p38 mitogen-activated protein kinase (MAPK).
Sourced in United States, Germany, United Kingdom, Macao, China, Sao Tome and Principe, Morocco, Sweden, Japan, Switzerland, France, India, Italy, Canada, Brazil
SP600125 is a small molecule compound that functions as a selective inhibitor of the c-Jun N-terminal kinase (JNK) signaling pathway. It is commonly used as a research tool to investigate the role of the JNK pathway in various cellular processes and disease models.
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
Sourced in United States, Germany, United Kingdom, China
LY294002 is a selective and potent inhibitor of phosphoinositide 3-kinase (PI3K). It functions by blocking the ATP-binding site of the PI3K enzyme, thereby inhibiting its catalytic activity.

More about "U 0126"

U0126: A Versatile Tool for MAPK/ERK Pathway Research U0126 is a widely-used pharmacological compound that has become an invaluable tool for researchers studying the mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways.
This selective inhibitor targets the MAPK kinase enzymes MEK1 and MEK2, which are essential components of the MAPK/ERK cascade.
The MAPK/ERK pathway plays a critical role in regulating fundamental cellular processes such as growth, differentiation, and survival in response to extracellular signals.
By blocking the activation of ERK1 and ERK2, the downstream effectors of MEK1/2, U0126 effectively inhibits MAPK/ERK signaling, making it a powerful tool for investigating the involvement of this cascade in various cellular and disease models.
Researchers can leverage the PubCompare.ai platform to discover optimized protocols for the use of U0126 and other related compounds like FBS, LY294002, SB203580, and SP600125.
This AI-driven research protocol comparison tool analyzes and compares protocols from literature, preprints, and patents, helping researchers identify the most accurate and reproducible methods for their studies.
By utilizing PubCompare.ai, researchers can acheive better, more reproducible results in their investigations of the MAPK/ERK pathway and the effects of U0126 on cellular processes.
The platform's advanced algorithms provide valuable insights into the optimal use of U0126 and other key compounds, enabling researchers to maximize the efficacy and reliability of their research.